The Data
/
Stocks
/ VTRS
Equity · Healthcare
$17.30
−0.06% vs prior close
Finazon · prior-day close, indicative (IEX-derived, not the official close)
1D
1M
3M
1Y
5Y
All
Price · Chart
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for VTRS to draw a line in its place.
Interactive VTRS price chart by TradingView (requires JavaScript).
Market cap
$19.9B
52-week range
$8.75 – $17.38
Avg volume
3.0M
as of Jul 17, 2026
About Viatris Inc.
Viatris is a global healthcare company that supplies medicines to patients in more than 165 countries and territories. Its portfolio includes generics (including complex products), branded medicines, and innovative drugs, supported by manufacturing, packaging, and distribution sites worldwide. In 2022–2024, Viatris completed several divestitures, including its biosimilars portfolio, women's healthcare business, API business in India, OTC business, and certain women's healthcare product rights, as well as commercialization rights in most Upjohn Distributor Markets. The company is headquartered in the U.S. with global centers in Pittsburgh, Shanghai, and Hyderabad.
Company
CEO
Scott A. Smith
Founded
2020
Headquarters
Pittsburgh
Exchange
NasdaqGS
Sector
Healthcare
Class
Equity
Insiders Form 4
Filings 5 sets
VTRS insider trades
SEC Form 4 · last 90 days · newest Form 4 filing 15 Aug 2026
Open-market buys
0
Open-market sells
0
Non-trade filings
2
Compensation mechanics
Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Date
Insider
Type
Shares
Value
15 Aug 2026
Enrietti Andrew
See Remarks
Option exercise
26,133
15 Aug 2026
Enrietti Andrew
See Remarks
Tax withheld
11,366
$184K
VTRS reported financials
SEC EDGAR XBRL
SEC EDGAR
VTRS reported revenue of $14.3B for the fiscal year ended 31 Dec 2025. Net income over the same period was −$3.5B.
Figure
Reported
Period
Revenue
$14.3B
31 Dec 2025
fiscal year
Net income
−$3.5B
31 Dec 2025
fiscal year
Diluted EPS
−$3.00
31 Dec 2025
fiscal year
Total assets
$35.0B
30 Jun 2026
at period end
Total equity incl. minority interest
$14.3B
30 Jun 2026
at period end
VTRS earnings
SEC EDGAR
Date
Period
EPS
Revenue
30 Jun 2026
Q2 2026
−$0.10
$3.76B
31 Mar 2026
Q1 2026
$0.15
$3.52B
31 Dec 2025
FY 2025
−$3.00
$14.30B
30 Sep 2025
Q3 2025
−$0.11
$3.76B
30 Jun 2025
Q2 2025
$0.00
$3.58B
31 Mar 2025
Q1 2025
−$2.55
$3.25B
31 Dec 2024
FY 2024
−$0.53
$14.74B
30 Sep 2024
Q3 2024
$0.08
$3.75B
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
12 of the 45 institutional funds we track reported a VTRS position for the quarter ended 30 Jun 2026 — a combined $369.2M; the latest of those filings landed 02 Sep 2026.
Fund
Action
Shares
Value
Man Group
Held (±25%)
−13.9% shares
3,523,052
$55.9M
Showing the 10 largest of 12 reported positions. The figures above count all of them.
VTRS fails-to-deliver
SEC CNS data
SEC
On 30 Sep 2026, 670 shares of VTRS failed to deliver (about $12K) — the latest of 4 consecutive trading days with recorded fails.
Settlement date
Shares failed
Notional
% of shares out
30 Sep 2026
670
$12K
<0.001%
29 Sep 2026
80
$1K
<0.001%
28 Sep 2026
1,416
$25K
<0.001%
25 Sep 2026
348
$6K
<0.001%
23 Sep 2026
475
$8K
<0.001%
21 Sep 2026
463
$8K
<0.001%
18 Sep 2026
1,057
$18K
<0.001%
17 Sep 2026
88,693
$1.5M
0.008%
14 Sep 2026
158,356
$2.6M
0.014%
11 Sep 2026
1,369
$22K
<0.001%
10 Sep 2026
895
$15K
<0.001%
09 Sep 2026
2,924
$49K
<0.001%
04 Sep 2026
600
$10K
<0.001%
The most recent congressional trade disclosed in VTRS is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 18 Nov 2025.
Date
Member
Type
Amount
18 Nov 2025
filed 15 Dec 2025
Gilbert Ray Cisneros, Jr.
house · Democrat–CA
Purchase
$1K–$15K
08 Apr 2025
filed 08 May 2025
Robert P. Bresnahan, Jr.
house · Republican–PA
Sale
$1K–$15K
31 Mar 2025
filed 07 Apr 2025
Gilbert Ray Cisneros, Jr.
house · Democrat–CA
Sale
$1K–$15K
25 Feb 2025
filed 27 Mar 2025
Robert P. Bresnahan, Jr.
house · Republican–PA
Purchase
$1K–$15K
10 Apr 2023
filed 19 May 2023
Daniel S. Goldman
house · Democrat–NY
Sale
$1K–$15K
06 Mar 2023
filed 17 Apr 2023
Daniel S. Goldman
house · Democrat–NY
Sale
$1K–$15K
31 Jan 2023
filed 24 Feb 2023
Daniel S. Goldman
house · Democrat–NY
Purchase
$1K–$15K
04 Mar 2021
filed 02 Sep 2022
Carol D. Miller
house · Republican–WV
Sale
$1K–$15K
Sources
Finazon prior-day close, indicative (IEX-derived, not the official close)
TradingView the price chart widget, drawn by TradingView from their own data
SEC EDGAR SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
SEC EDGAR SEC EDGAR 13F filings
SEC SEC fails-to-deliver (CNS) data
House disclosures U.S. House of Representatives financial disclosures
SEC EDGAR Valuation computed from SEC EDGAR filings